ID
38908
Beschreibung
Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form is to be filled in (repeatedly, if necessary) during the study and/or at the end of the study in case of non-serious adverse events.
Link
https://clinicaltrials.gov/ct2/show/NCT01476046
Stichworte
Versionen (3)
- 22.10.19 22.10.19 -
- 22.10.19 22.10.19 -
- 12.11.19 12.11.19 - Sarah Riepenhausen
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
12. November 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Phase I Trial of Intravenous TNFR1 Antagonist GSK1995057 in Healthy Subjects - NCT01476046
Non-serious AE
- StudyEvent: ODM
Beschreibung
Non-serious adverse event
Alias
- UMLS CUI-1
- C1518404
Beschreibung
Hidden
Datentyp
text
Alias
- UMLS CUI [1,1]
- C2348184
- UMLS CUI [1,2]
- C1518404
Beschreibung
Diagnosis or Sign/Symptom
Datentyp
text
Alias
- UMLS CUI [1]
- C0011900
- UMLS CUI [2]
- C3540840
Beschreibung
Hidden
Datentyp
text
Alias
- UMLS CUI [1]
- C2826798
Beschreibung
Hidden
Datentyp
text
Alias
- UMLS CUI [1]
- C1140263
Beschreibung
Hidden
Datentyp
text
Alias
- UMLS CUI [1]
- C3898442
Beschreibung
Hidden
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Beschreibung
Start Date/Time
Datentyp
partialDatetime
Alias
- UMLS CUI [1]
- C2826806
Beschreibung
if Recovered/Resolved (with or without sequelae) provide End Date and Time
Datentyp
integer
Alias
- UMLS CUI [1]
- C1705586
Beschreibung
if applicable
Datentyp
partialDatetime
Alias
- UMLS CUI [1]
- C2826793
Beschreibung
Non-serious adverse event frequency
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0439603
- UMLS CUI [1,2]
- C1518404
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1]
- C1710066
Beschreibung
Adverse Event Maximum Grade
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
Beschreibung
[hidden]
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
- UMLS CUI [2,1]
- C0518690
- UMLS CUI [2,2]
- C1518404
Beschreibung
Action regarding Investigational Product because of non-serious adverse event
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1704758
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Beschreibung
subject withdrawal because of non-serious adverse event
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0422727
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Beschreibung
AE possibly caused by investigational product
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1518404
Beschreibung
[hidden] If AE start and end time are used this item must be hidden.
Datentyp
time
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C1518404
Beschreibung
[hidden]
Datentyp
time
Alias
- UMLS CUI [1,1]
- C1272706
- UMLS CUI [1,2]
- C1517741
- UMLS CUI [1,3]
- C0178602
- UMLS CUI [1,4]
- C0439659
- UMLS CUI [1,5]
- C1518404
Ähnliche Modelle
Non-serious AE
- StudyEvent: ODM
C1264639 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C3540840 (UMLS CUI [2])
C0231175 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C0518690 (UMLS CUI [2,1])
C1518404 (UMLS CUI [2,2])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0085978 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C1518404 (UMLS CUI [1,2])
C1517741 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0439659 (UMLS CUI [1,4])
C1518404 (UMLS CUI [1,5])